drugset / Trial / NCT03817567
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
Phase 1/2
Unknown
50 enrolled
Sinocelltech Ltd.
Tianjin Medical University Cancer Institute and Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced esophageal squamous cell carcinoma progressed following treatment with taxane/platinum/fluorouracil.
Timeline
- Start
- 2018-07-17
- Primary completion
- 2019-11-30
- Completion
- 2020-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCT200 | Monoclonal antibody | 8 mg/kg | — |